Denali Therapeutics Inc. — Q3 2023 Form 10-Q
Reporting period: Quarter and nine months ended September 30, 2023. Denali is a clinical-stage biopharmaceutical company focused on neurodegenerative diseases; it has no approved products and has generated no product-sales revenue.
Financial results and liquidity
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Collaboration revenue | $1.3 million | $3.6 million | $330.5 million | $98.2 million |
| Research and development expense | $89.7 million | $87.8 million | $316.1 million | $266.6 million |
| General and administrative expense | $25.3 million | $23.3 million | $78.6 million | $67.0 million |
| Operating loss | $113.8 million | $107.5 million | $64.1 million | $235.4 million |
| Net loss | $99.4 million | $103.3 million | $25.8 million | $227.3 million |
| Net loss per share, basic and diluted | $0.72 | $0.84 | $0.19 | $1.85 |
- Nine-month revenue included $293.9 million recognized after Biogen exercised its option to license Denali’s ATV:Abeta program. The large year-over-year decline in nine-month net loss therefore reflects collaboration revenue, not product sales or profitability.
- Interest and other income was $14.4 million in Q3 and $38.4 million for the nine months, versus $4.2 million and $8.1 million in the comparable 2022 periods.
- At September 30, cash and cash equivalents were $148.0 million and marketable securities totaled $969.2 million, or approximately $1.12 billion combined. Total assets were $1.24 billion; stockholders’ equity was $1.12 billion; accumulated deficit was $996.7 million.
- Nine-month operating cash use was $259.3 million, compared with $172.1 million in 2022. Investing activities provided $176.3 million, largely from net maturities and sales of marketable securities; financing activities provided $13.1 million. Cash, cash equivalents and restricted cash declined $70.0 million.
- No financial debt is identified on the balance sheet. Operating lease liabilities totaled $53.9 million. Current liabilities were $71.2 million, down from $363.9 million at year-end 2022, principally because the Biogen contract liability was recognized as revenue.
Changes, outlook and material developments
- Q3 net loss narrowed 4% year over year, while operating loss widened about 6%. For the nine months, net loss narrowed substantially as collaboration revenue rose; operating expenses increased 18%.
- Nine-month R&D expense rose $49.5 million. Drivers included a $30.0 million F-star contingent-consideration payment triggered by an ETV:IDS milestone, higher ETV:IDS and personnel costs, and $7.9 million of accelerated depreciation after terminating the prior Salt Lake City lease. Management expects R&D and G&A expenses to increase as programs advance.
- Management said existing cash, cash equivalents and marketable securities should fund projected operations through at least the 12 months after the November 7, 2023 filing date. It expects substantial future funding needs; additional financing may not be available on acceptable terms.
- Clinical and portfolio updates: DNL310 continued in Phase 1/2 and Phase 2/3 development for Hunter syndrome; DNL126’s IND for MPS IIIA was accepted and Phase 1/2 start-up was underway. The Biogen LRRK2 program was being refocused around the LUMA study, with planned enrollment changes; management said the changes were not based on safety or efficacy data.
- Denali and Takeda discontinued Alzheimer’s clinical development of TAK-920/DNL919 and shifted research to backup molecules. The filing reports moderate, reversible hematologic effects at the highest Phase 1 dose and a potential narrow therapeutic window. Separately, Sanofi later announced discontinuation of eclitasertib development in CLE after its Phase 2 study missed the primary endpoint; development in UC continued.
- Commitments included $49.9 million of non-cancellable Lonza manufacturing purchase commitments and $37.8 million under certain other clinical and manufacturing agreements. Management reported total non-refundable purchase commitments of $87.7 million, some subject to Takeda cost sharing, and $53.9 million of recorded lease liabilities.
- Key risks include clinical-trial success and timing, safety and regulatory approval, dependence on collaborators and contract manufacturers, manufacturing scale-up and Utah-site build-out delays, intellectual-property protection, and the need for additional capital. Management reported disclosure controls effective at a reasonable-assurance level and no material litigation pending.
Important facts for investors to verify
- How much of reported collaboration revenue is nonrecurring, and what future milestone, option or partner payments are realistically attainable?
- Whether DNL310 and other lead programs produce durable, clinically meaningful results in later-stage trials, beyond interim or exploratory data.
- Whether the LRRK2 study revisions and partner arrangements support a timely, informative efficacy readout.
- Whether cash burn, manufacturing commitments and clinical spending remain consistent with management’s stated funding runway and assumptions.
- Progress, costs and timing of the Utah manufacturing-site build-out, and any resulting supply or trial delays.